Today, the World Federation of Incontinence and Pelvic Problems (WFIPP) released a statement of partnership and collaboration with award-winning MUVON Therapeutics AG exponentially enhancing global awareness and knowledge on novel experimental breakthrough treatment options for stress-urinary incontinence though an educational program. Mary Lynne van Poelgeest-Pomfret, the President of WFIPP and Deana Mohr, CEO of MUVON Therapeutics share a unified vision to create a world wh

MUVON Therapeutics was selected by the Lichtsteiner Foundation to become a part of their supported community of pioneering innovators. For the Lichtsteiner Foundation Testimonial video series showcasing their community, CEO and co-founder Deana Mohr spoke about MUVON Therapeutics' mission to establish personalised treatments for the regeneration of skeletal muscle as primary standard of care. You can find the video under the following link: Community | Lichtsteiner Foundatio

MUVON Therapeutics, a spin-off from the University of Zurich developing a platform technology for the regeneration of skeletal muscle tissue, is proud to announce that its CEO and co-founder Deana Mohr, PhD, has been listed on the Top 30 In Vivo’s '2022 Rising Leaders' . The list features 30 investors, entrepreneurs and innovators with biopharma and medtech businesses from all over the world who drive health initiatives forward with their talent, creativity and strong leaders